EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 3.0

Safety and Efficacy of TACE Combined with Lenvatinib and Pembrolizumab in Advanced Hepatocellular Carcinoma (BCLC C): A Retrospective Study [Retraction]

Zeran Yang, Jian Li, Long Jin

Journal of Hepatocellular Carcinoma · 2026-11 · Volume 13 · 1-1

DOI: 10.2147/jhc.s672578 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Hepatocellular Carcinoma, 2026-11. Verfasst von Zeran Yang und 2 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Zitieren

APA

Yang, Z., Li, J., & Jin, L. (2026). Safety and Efficacy of TACE Combined with Lenvatinib and Pembrolizumab in Advanced Hepatocellular Carcinoma (BCLC C): A Retrospective Study [Retraction]. Journal of Hepatocellular Carcinoma, Volume 13, 1-1. https://doi.org/10.2147/jhc.s672578

Vancouver

Yang Z, Li J, Jin L. Safety and Efficacy of TACE Combined with Lenvatinib and Pembrolizumab in Advanced Hepatocellular Carcinoma (BCLC C): A Retrospective Study [Retraction]. Journal of Hepatocellular Carcinoma. 2026;Volume 13:1-1. doi:10.2147/jhc.s672578

BibTeX
@article{Yang2026,
  author = {Yang, Zeran and Li, Jian and Jin, Long},
  title = {Safety and Efficacy of TACE Combined with Lenvatinib and Pembrolizumab in Advanced Hepatocellular Carcinoma (BCLC C): A Retrospective Study [Retraction]},
  journal = {Journal of Hepatocellular Carcinoma},
  year = {2026},
  volume = {Volume 13},
  pages = {1--1},
  doi = {10.2147/jhc.s672578}
}
Kostenlos starten →